DRUM is a consortium whose aim is to transform understanding of the drivers of antimicrobial resistance (AMR) in Eastern Africa, and design interventions to mitigate AMR spread by determining specific drivers of transmission. The DRUM consortium seeks to address how human behaviour and antibacterial usage in urban and rural Africa leads to the transmission of AMR amongst E. coli and K. pneumoniae in humans, animals and the environment and influences the clinical impact of drug-resistant bloodstream infection (DR-BSI) in humans. DRUM seeks to develop agent-based models that will enable the prediction of how these transmission pathways can be interrupted. DRUM’s vision is to establish Ugandan and Malawian sites as sustainable model settings for interdisciplinary study and mitigation of AMR by embedding a One Health strategy at the heart of a consortium that will generate outputs applicable to similar communities throughout East and Southern Africa and beyond.
AFIDEP’s work is specifically to identify and address barriers between in-country sectors involved in AMR control for the delivery of appropriate policy.
Problem: The growing threat of drug-resistant bacteria is well recognized. Low- and middle- income countries are likely to be more severely affected due to overstretched health systems and poor access to alternative antibiotic regimes. Developing and implementing effective policy to tackle antibacterial resistance (ABR) is vital and will require coordination between a wide range of different sectors such as human and animal health, the environment and waste management and agriculture.
Type of study: Qualitative research study exploring the process of policy development and implementation for antibacterial resistance (ABR) in Uganda and Malawi.